BioChaperone PramGluExe

BioChaperone PramGluExe is a **preclinical triple-hormone peptide combination therapy** from **Adocia** for **obesity**. It combines **pramlintide**, **glucagon**, and **exenatide** in a single formulation using Adocia's proprietary **BioChaperone** formulation platform, which is intended to enable co-formulation of peptide hormones and improve usability and potentially pharmacologic performance. Mechanistically, the combination is designed to engage **amylin receptors** via pramlintide, the **glucagon receptor** via glucagon, and the **glucagon-like peptide 1 receptor** via exenatide, aiming to produce complementary effects on satiety, energy balance, glycemic control, and weight reduction. It has been described in Adocia's pipeline as a biologic multi-hormonal obesity program and, based on the provided context, remained in preclinical development around 2021 to 2022.

Other names

pramlintide + glucagon + exenatide